About 30 percent receive diabetes-specific screening; no form of glucose screening for 31.1 percent
WEDNESDAY, Nov. 11, 2015 (HealthDay News) — About 30 percent of adults with severe mental illness (SMI) taking antipsychotic medications undergo diabetes-specific screening using validated screening measures, according to a study published online Nov. 9 in JAMA Internal Medicine.
Christina Mangurian, M.D., from the University of California in San Francisco, and colleagues conducted a retrospective cohort study to examine diabetes screening among 50,915 publicly insured adults with SMI taking antipsychotic medications. The authors also examined characteristics predictive of screening. Data were examined during two study periods: Jan. 1, 2009, to Dec. 31, 2009, and Oct. 1, 2010, to Sept. 30, 2011.
The researchers found that 30.1 percent of the cohort received diabetes-specific screening. In a yearlong period, 31.1 percent received no form of glucose screening. Having at least one outpatient primary care visit during the period examined was the strongest correlate of diabetes-specific screening (adjusted prevalence ratio, 1.8; P < 0.001).
“Growing evidence supports the value of screening for diabetes mellitus in higher-risk populations, such as those receiving treatment with antipsychotic medications, including first-generation and second-generation agents that commonly result in co-occurring obesity,” the authors write. “Future studies should explore barriers to screening in this vulnerable population.”
One author disclosed financial ties to the pharmaceutical industry.
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Copyright © 2015 HealthDay. All rights reserved.
